Using advanced imaging techniques to improve diagnosis and understanding of heart failure with preserved ejection fraction
Multimodality Imaging (Cardiovascular Magnetic Resonance Imaging, Echocardiography, and Nuclear Medicine Imaging) in the Screening, Diagnosis and Risk Stratification of Heart Failure With Preserved Ejection Fraction (HFpEF).
This study is trying to see if advanced imaging techniques can help doctors better diagnose and understand heart failure with preserved ejection fraction so they can help patients sooner.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 430 (estimated) |
| Sex | All |
| Sponsor | Chinese Academy of Medical Sciences, Fuwai Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT04603404 on ClinicalTrials.gov |
What this trial studies
This study investigates the cardiac features and risk factors associated with heart failure with preserved ejection fraction (HFpEF) using a combination of advanced imaging techniques, including cardiovascular magnetic resonance imaging, echocardiography, and nuclear medicine imaging. By leveraging large datasets and artificial intelligence, the study aims to enhance early diagnosis and understanding of the disease, which is often overlooked due to its nonspecific clinical presentation. The research focuses on identifying subclinical changes in cardiac structure and function that are critical for timely intervention. The findings could lead to improved management strategies for patients suffering from HFpEF.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with heart failure symptoms and a left ventricular ejection fraction of 50% or higher.
Not a fit: Patients with specific types of cardiomyopathy, severe arrhythmias, or those who refuse to participate will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier diagnosis and better management of heart failure with preserved ejection fraction, ultimately improving patient outcomes.
How similar studies have performed: While there have been studies exploring various imaging techniques in heart failure, this multimodal approach combined with artificial intelligence is relatively novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * left ventricular ejection fraction (LVEF)≥50%； * N-terminal pro-b type natriuretic peptide (NT-proBNP)\>220pg/ml or b type natriuretic peptide (BNP) \>80 pg/ml; * symptoms and syndromes of heart failure; * At least one criteria of cardiac structure (left ventricular hypertrophy, or left atrial enlargement) and function abnormalities (based on tissue doppler, color doppler). Exclusion Criteria: * Special types of cardiomyopathy, including hypertrophic cardiomyopathy, restricted cardiomyopathy, etc. * Infarction, myocardial fibrosis caused by ischemic cardiomyopathy and acute coronary syndrome ; * Severe arrhythmia; * Severe primary cardiac valvular disease; * Restrictive pericardial disease; * Refuse to participate in the study.
Where this trial is running
Beijing, Beijing Municipality
- Fuwai Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Principal investigator: Minjie Lu, PhD — Fuwai Hospital, National Center for Cardiovascular Diseases.
- Study coordinator: Minjie Lu, PhD
- Email: coolkan@163.com
- Phone: 86 10 88396941
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.